Showing 1771-1780 of 7024 results for "".
What’s New in Psoriasis
https://practicaldermatology.com/conferences/science-of-skin-summit-2025/tbd/39743/Chris Bunick, MD, FAAD, talks about new therapeutic directions, real‑world data, and challenges in psoriasis management. This video was recorded at the Science of Skin Summit in Austin, TX.Growing into the Role of a KOL
https://reachmd.com/programs/practical-dermatology/tbd/39738/Michael H. Gold, MD, founder/medical director of Gold Skin Care Center, shares his path and strategies becoming a key opinion leader in dermatology. This video was recorded at the Science of Skin Summit in Austin, TX.DermwireTV: Deucravacitinib Maintains Efficacy in PsO at 3 Years
https://reachmd.com/programs/practical-dermatology/dermwiretv-deucravacitinib-maintains-efficacy-in-pso-at-3-years/37249/In this episode of DermwireTV, deucravacitinib maintains efficacy for plaque psoriasis through 3 years in a new analysis; GLP-1 medications may be fueling a rise in aesthetic procedures, according to new research; and Drs. Tina Bhutani and Lisa Swanson weigh in on transitioning from academia to privDermwireTV: DermaRite Issues Recall for Several Hand Soaps
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-dermarite-issues-recall-for-several-hand-soaps/37113/In this episode, new research shows switching between interclass biologics may be safe and effective for psoriasis patients; DermaRite recalls 4 skin care products over contamination concerns; and awareness grows for generalized pustular psoriasis through a new global awareness campaign.DWTV Extra: DermLink Scholars Founder Dr. Kelly Frasier
https://practicaldermatology.com/series/dermwire-tv/DWTV-Extra-DermLink-Scholars-Founder-Dr-Kelly-Frasier/36554/DermLink Scholars Founder and CEO Kelly Frasier, DO, MS, CRC, and Alina G. Bridges, DO, FAAD, discuss the organization and its inaugural virtual conference Saturday, August 2. For more information, go to dermlinkscholars.com.FDA Grants Interchangeability to HADLIMA
https://practicaldermatology.com/series/dermwire-tv/fda-grants-interchangeability-to-hadlima/35962/In this week's DermwireTV, the FDA grants full interchangeability to HADLIMA; new research shows the impact of UV exposure on global skin cancer cases; and coverage from Music City SCALE addresses barriers to patient access to new therapies.Rosacea Treatment Options and Strategies
https://reachmd.com/programs/practical-dermatology/rosacea-treatment-options-and-strategies/35893/Joel L. Cohen, MD, FAAD, and Hilary Baldwin, MD, talk at Music City SCALE 2025 about the latest treatment options for rosacea and strategies for getting patient buy-in.Nail Disease and JAK Inhibitor Safety
https://reachmd.com/programs/practical-dermatology/nail-disease-and-jak-inhibitor-safety/35897/Brad Glick, DO, talks about the basics of nail anatomy, physiology, disease presentation, and treatments, as well as the safety of JAK inhibitors, at Music City SCALE 2025.Sunscreen as Self-Care
https://practicaldermatology.com/series/c-suite-chats/sunscreen-as-self-care/33249/Arielle Moody, product developer at Mama Sol, talks about the importance of sunscreen in beauty routines and how her company is attempting to make it more appealing.Novel PsO Drug Could Be 'Closest Perception of a Cure,' Dr. Strober Says at Maui Derm
https://reachmd.com/programs/practical-dermatology/novel-pso-drug-could-be-closest-perception-of-a-cure-dr-strober-says-at-maui-derm/32922/A novel monoclonal antibody targeting IL-23 for the treatment of psoriasis offers an extended half-life that will be a key differentiator for patients, according to Bruce Strober, MD, PhD.